BioLineRx Ltd (NASDAQ:BLRX) Q4 2019 Earnings Conference Call - Final Transcript
Mar 12, 2020 • 10:00 am ET
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx's Fourth Quarter and Full Year 2019 Conference Call. [Operator Instructions] Following the management's formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions].
I'd now like to turn over the call to Timothy McCarthy of LifeSci Advisors to read the Safe Harbor statement. Tim, please go ahead.
Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call other than historical facts are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include, but are not limited to the risk factors and other qualifications contained in BioLineRx's annual report on Form 20-F, quarterly reports filed in the 6-K and other reports filed by BioLineRx with the SEC to which your attention is directed.
Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements.
At this time, it's now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.
Philip A. Serlin
Thank you, Tim, and good morning, everyone. And thank you for joining us on our fourth quarter earnings conference call today. Earlier this morning, we issued our Q4 earnings press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-K.
I will begin with the brief review of our programs and activities, recap our upcoming milestones over the next several quarters. And then, Mali Zeevi, our Chief Financial Officer will provide a short discussion of our financial results. We will then open up the call to your questions. Also during the call for Q&A, are Abi Vainstein, our Vice President, Clinical Development; and Ella Sorani, our Vice President, Research and Development.
During the fourth quarter, we achieved a significant development milestone with the announcement of preliminary Phase II data from the triple combination arm of our ongoing COMBAT/KEYNOTE-202 clinical trial that we are running in collaboration with Merck. Recall that this trial is evaluating BL-8040, which we're now calling motixafortide in combination with Merck's, KEYTRUDA and chemotherapy as a second line treatment for pancreatic ductal adenocarcinoma or PDAC.
PDAC is a particularly challenging form of cancer due to its aggressive
aggressive biology and late stage at the time of detection. Approximately 50% of patients are initially diagnosed at stage four. These factors contribute to a very poor prognosis for these patients. Moreover, PDAC is also a cold tumor that is not receptive to currently available immuno-oncology agents, so more effective treatment options are desperately